## ACAD: ACADIA Pharmaceuticals Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 7.4% in mid entry zone (4.0-10.0%), top quartile (88th pct) cross-sectional ranking. Short-term MRS_5 (2.5%) confirms momentum alignment. Outperforming sector by 7.7%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($25.37)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Its Strong 1-Year Share Price Rally**
- Source: Simply Wall Street | 20251213T190906 | Bullish | Relevance: 100%
- ACADIA Pharmaceuticals has seen significant share price growth over the past year, rewarding patient investors. The stock is considered modestly undervalued with a fair value of $29.32 against its current $27.15, driven by its pipeline momentum and expected clinical readouts by 2027. However, potential risks include tighter U.S. drug pricing and heavy reliance on NUPLAZID.

**2. Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome**
- Source: Eagle-Tribune | 20251212T130911 | Bullish | Relevance: 100%
- Acadia Pharmaceuticals has received FDA approval for DAYBUE® STIX, a new powder formulation of trofinetide for treating Rett syndrome in patients aged two and older. This dye- and preservative-free oral solution offers increased flexibility in administration and taste, based on bioequivalence to the existing DAYBUE oral solution. The new formulation will be rolled out in limited quantities in Q1 2026, with broader availability in Q2 2026.

**3. Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome**
- Source: Business Wire | 20251212T130910 | Bullish | Relevance: 100%
- Acadia Pharmaceuticals Inc. has received FDA approval for DAYBUE STIX (trofinetide) for oral solution, an innovative dye- and preservative-free powder formulation for treating Rett syndrome in patients aged two years and older. This new formulation offers greater flexibility in dose volume and taste compared to the original oral solution while maintaining the same efficacy and safety profile. DAYBUE STIX will be available on a limited basis in Q1 2026, with broader availability in Q2 2026, alongside the continued availability of the existing oral solution.

**4. Acadia Pharmaceuticals stock price target raised by Stifel to $25 from $24**
- Source: Investing.com UK | 20251211T131009 | Somewhat-Bullish | Relevance: 100%
- Stifel has increased its price target for Acadia Pharmaceuticals (NASDAQ:ACAD) to $25.00 from $24.00, maintaining a Hold rating despite the company's strong year-to-date performance and recent intellectual property victory for Nuplazid. The firm indicates that Acadia's future stock performance largely depends on renewed growth from its Daybue product or positive Phase 2 data for ACP-204 in Alzheimer’s disease psychosis, expected in mid-2026. InvestingPro analysis suggests the stock is currently undervalued, with a PEG ratio of 0.18.

**5. Hohimer Wealth Management LLC Decreases Position in ACADIA Pharmaceuticals Inc. $ACAD**
- Source: MarketBeat | 20251214T130942 | Somewhat-Bullish | Relevance: 100%
- Hohimer Wealth Management LLC reduced its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 26.6% in the second quarter, now holding 117,883 shares valued at $2.54 million. Despite insider sales totaling over $1 million recently, institutional investors collectively own approximately 96.71% of the company's stock. ACADIA Pharmaceuticals has also reported strong earnings, beating EPS estimates and growing revenue by 11.3%, with analysts maintaining a "Moderate Buy" consensus rating and an average price target of $28.68.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Stifel | $25 | $24 | +4% |
| 2025-12-02 | Mizuho | $29 | $24 | +21% |
| 2025-11-17 | JP Morgan | $31 | $33 | -6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Stifel | main | Hold |
| 2025-12-02 | Mizuho | main | Neutral |
| 2025-11-17 | JP Morgan | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 3 ($1.01M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Baker Bros. Advisors: 25.4% (0.0%)
- Blackrock Inc.: 12.0% (-1.9%)
- Vanguard Group Inc: 9.0% (-0.6%)
- State Street Corpora: 4.3% (+17.4%)
- RTW Investments LP: 4.2% (-20.6%)

### Key Risks

1. Elevated short interest (8.2%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Quality metrics strong (ROE 35%, margin 25%). Balance sheet: strong liquidity (3.0x), low leverage (D/E 0.45). Analyst sentiment positive (2 raises, avg +12%). Insider selling cluster ($1.0M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.6B |
| Beta | 0.67 |
| 52W Range | $13.40 - $27.73 |
| Short Interest | 8.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.42 |
| Forward P/E | 33.4 |
| Current P/E | 33.3 |
| YoY Growth | -0.2% |
| EPS Direction | RISING |

### Technicals

MRS_20 stable at 7.4% (minimal 5-day change). Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 88th percentile. MRS_5 at 2.5% confirms short-term momentum alignment. AM_20 at 7.7% shows strong absolute momentum above own 20MA. Outperforming sector by 7.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 7.42% (CS: 88) | Strong |
| RSI_14 | 69.6 | Neutral |
| MACD Histogram | 0.13 | Bullish |
| vs SMA20 | 1.077x | Above |
| vs SMA50 | 1.170x | Above |
| vs SMA200 | 1.277x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $27.15
- **Stop Loss:** $25.37 (6.6% risk)
- **Target:** $29.82 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 561
- **Position Value:** $15,231.15
- **Portfolio %:** 15.23%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-25 (Est: $0.14)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.15 | $0.42 | +189.0% |
| 2025Q2 | $0.14 | $0.16 | +15.3% |
| 2025Q1 | $0.11 | $0.11 | +4.5% |
| 2024Q4 | $0.22 | $0.86 | +292.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*